Lipocalins as new tools for improved therapy and diagnosis of allergy


The present invention relates to the use of human Lipocalin-2 (LCN-2) to enhance the efficacy of Specific Allergen Immunotherapy (SIT or AIT).

Category

Life Science

Projectnumber

P1400116

Patent Status

  • EP patent pending
  • PCT application in preparation

Description

The present invention relates to the use of human Lipocalin-2 (LCN-2) to enhance the efficacy of Specific Allergen Immunotherapy (SIT or AIT). Loading LCN-2 with siderophores complexed with iron enables improved allergy therapy. Furthermore, LCN-2 is presented as a biomarker for allergy diagnosis and for monitoring of SIT. Hence, using LCN-2 as a biomarker and a therapeutic allows improved patient selection followed by SIT with higher efficacy.

Application

Therapy and diagnosis of allergy

Benefits

  • Better patient selection before SIT
  • Improved success of SIT by counterbalancing Th2 immunity and avoidance of Th2 adjuvants
  • Therapy monitoring during SIT
  • Higher reliability and efficacy of SIT

Cooperation Options

  • Collaboration
  • Licensing
  • Purchase

Contact

Dipl.-Ing. Dr. Manfred Lampl
Schutzrechtsmanagement
+ 43 1 501 75 - 553